Page 3 - Anthony Windebank News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease. The deadly neurological disease has few treatment options. NurOwn, a stem cell therapy, is at the center of a yearslong lobbying campaign by patients seeking access to experimental medicines. But the FDA has repeatedly rebuffed drugmaker Brainstorm. The agency says the company's only study failed to show a benefit for patients. The review is the starkest test yet of FDA's commitment to “regulatory flexibility” to help patients with rare, deadly conditions. Advocates s...

“FDA is the 800-pound gorilla here, and if they’re convinced that the drug doesn’t work, it’s very hard to change their minds,” a former FDA official said.

The FDA is meeting this week to consider NurOwn, a much-debated treatment for Lou Gehrig’s disease. The agency says the treatment hasn't been shown to work.

The FDA is meeting this week to consider NurOwn, a much-debated treatment for Lou Gehrig’s disease. The agency says the treatment hasn't been shown to work.

The FDA is meeting this week to consider NurOwn, a much-debated treatment for Lou Gehrig’s disease. The agency says the treatment hasn't been shown to work.